49 7071 9883 0
Full-time employees: 904
|Mr. Pierre Kemula B.Sc.||MD, CFO & Member of Management Board||588.6k||N/A||1975|
|Dr. Igor Splawski M.Sc., Ph.D.||Chief Scientific Officer & Member of Management Board||518.61k||N/A||1969|
|Dr. Antony Blanc Ph.D.||MD, Chief Bus. Officer, Chief Commercial Officer & Member of Management Board||500.99k||N/A||1970|
|Mr. Malte Greune Ph.D.||COO, Member of Management Board & MD||457.76k||N/A||1965|
|Dr. Ulrike Gnad-Vogt M.D., Ph.D.||Sr. VP & Area Head of Oncology||375.84k||N/A||1973|
|Dr. Alexander Zehnder M.B.A., M.D.||CEO, MD & Member of Management Board||N/A||N/A||1970|
|Dr. Myriam Mendila M.D.||Chief Devel. Officer, MD & Member of the Management Board||N/A||N/A||1966|
|Dr. Sarah Fakih||VP Corp. Communications & Investor Relations||N/A||N/A||N/A|
|Mr. Marco Rau L.L.M., Ph.D.||Gen. Counsel||N/A||N/A||N/A|
|Mr. Thorsten Schuller||Head of Corp. Communications||N/A||N/A||N/A|
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
CureVac N.V.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.